Avoro Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Avoro Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,497,042	Closed	-$17M	–	39
2018 Q3	$17M	Hold	4,497,042	–	–	0.78%	23
2018 Q2	$14M	Sell	4,497,042 -195,301	-4%	-$593K	0.54%	30
2018 Q1	$11.2M	Buy	4,692,343 +800,000	+21%	+$2.66M	0.54%	30
2017 Q4	$15.2M	Sell	3,892,343 -743,402	-16%	-$2.46M	0.99%	24
2017 Q3	$11.7M	Buy	4,635,745 +831,000	+22%	+$2.28M	0.91%	24
2017 Q2	$10.5M	Hold	3,804,745	–	–	1.33%	22
2017 Q1	$7.42M	Buy	3,804,745 +2,663,596	+233%	+$3.39M	0.95%	27
2016 Q4	$1.2M	Buy	+1,141,149	New	+$1.3M	0.24%	36
2015 Q1	–	Sell	-550,670	Closed	-$1.64M	–	35
2014 Q4	$1.64M	Buy	+550,670	New	+$1.51M	1.11%	23

Other funds holding CPRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Avoro Capital Advisors's CPRX Position: Q4 2018 in Review

Avoro Capital Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2018, closing a stake of 4,497,042 shares — an estimated $17M sold.

Avoro Capital Advisors first reported a position in CPRX in Q4 2014 and held it in 9 quarters. The position peaked at $17M in Q3 2018. 86 funds tracked by Wall St. Rank hold CPRX as of Q4 2018.

Avoro Capital Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2018 after selling out during the quarter.
Avoro Capital Advisors sold 4,497,042 Catalyst Pharmaceutical shares in Q4 2018, an estimated $17M.
Avoro Capital Advisors first reported a position in Catalyst Pharmaceutical in Q4 2014 and held it in 9 quarters.
Avoro Capital Advisors's Catalyst Pharmaceutical position peaked at $17M in Q3 2018.
86 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2018.

Based on Avoro Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.